Clinical Data In 2014 Could Trigger Private Biotech Financings
This article was originally published in Start Up
Executive Summary
Despite difficulties financing late-stage trials, several private companies are expecting Phase II and III data that should help shape public investor sentiment this year. Familiar compounds in new guises lead the way.
You may also be interested in...
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
Russian, Korean Pharmas Lead $42.5M Argos Financing, Take Local Rights
The personalized immunotherapy developer partnered with two foreign pharmas but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.
CROs And Biopharma Weigh The Balance Of Risk And Responsibility
Biopharmaceutical companies have been outsourcing R&D activity to CROs for a while, but neither they nor CROs have sorted out which side should bear the burden of what kind of risk and how to best structure operations.